Revival of 5-HT3 antagonism as treatment of IBS-D?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea.Clinical and experimental gastroenterology · 2017
   Review
2. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis.World journal of gastroenterology · 2016
   Article
3. Association of genetic polymorphisms in HTR3A and HTR3E with diarrhea predominant irritable bowel syndrome.International journal of clinical and experimental medicine · 2015
   Article

Corrections and comments

• Comment on
  A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea.2014

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as